Imugene (AU:IMU)
ASX:IMU
Want to see AU:IMU full AI Analyst Report?
IMU Stock Chart & Stats
AU$0.33
>-AU$0.01(-2.22%)
At close: 4:00 PM EST
AU$0.33
>-AU$0.01(-2.22%)
Day’s Range― - ―
52-Week RangeAU$0.09 - AU$0.71
Previous CloseN/A
Volume11.90M
Average Volume (3M)877.83K
Market Cap
AU$37.84M
Enterprise ValueAU$29.56M
Total Cash (Recent Filing)AU$14.14M
Total Debt (Recent Filing)AU$5.02M
Price to Earnings (P/E)―
Beta1.96
Next Earnings
Sep 02, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.22
Shares Outstanding415,835,050
10 Day Avg. Volume850,615
30 Day Avg. Volume877,834
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.15
Price to Sales (P/S)21.99
P/FCF Ratio-1.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.25Price Target Upside-24.24% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.14
Revenue Forecast (FY)AU$5.00M
Bulls Say, Bears Say
Bulls Say
Diverse Immuno-oncology PipelineImugene operates multiple, distinct immuno-oncology platforms (oncolytic viruses, B‑cell activators, CAR T and CAR T‑engagers). This platform diversification raises the probability of a value‑inflection event across programs, spreads scientific risk and supports multiple partnership or licensing pathways over time.
Conservative Capital StructureA low debt-to-equity ratio and moderate equity share indicate limited financial leverage, giving the company durable flexibility to fund R&D or withstand clinical timelines. Reduced leverage lowers solvency risk and preserves strategic optionality for licensing or staged trial investments over months.
Free Cash Flow Exceeds Net IncomeReported free cash flow exceeding accounting net loss suggests management can generate or conserve cash net of capital spending, possibly via timing, grants or disciplined capex. This dynamic can extend operational runway and support program advancement while limiting near-term financing needs.
Bears Say
Severe Revenue ContractionA pronounced revenue collapse indicates loss of material revenue streams and confirms the company remains development‑stage without recurring product sales. Over a multi‑month horizon this heightens dependence on external capital or partnerships to fund ongoing clinical programs and increases execution risk.
Persistent Negative Profitability And ReturnsDeeply negative margins and severely negative ROE show the business is not generating returns on equity and is absorbing capital. Such structural unprofitability curtails internal funding for trials, risks shareholder dilution through future raises, and challenges long‑term value creation absent major clinical or licensing successes.
Negative Operating Cash FlowOngoing operating cash outflows mean core activities consume cash rather than fund themselves. This structural cash burn necessitates recurring financing or partner support to sustain R&D programs, adding execution and financing risk over the coming months if clinical milestones are delayed.
Imugene News
IMU FAQ
What was Imugene’s price range in the past 12 months?
Imugene lowest share price was AU$0.09 and its highest was AU$0.71 in the past 12 months.
What is Imugene’s market cap?
Imugene’s market cap is AU$37.84M.
When is Imugene’s upcoming earnings report date?
Imugene’s upcoming earnings report date is Sep 02, 2026 which is in 105 days.
How were Imugene’s earnings last quarter?
Imugene released its earnings results on Feb 25, 2026. The company reported -AU$0.13 earnings per share for the quarter, beating the consensus estimate of -AU$0.34 by AU$0.21.
Is Imugene overvalued?
According to Wall Street analysts Imugene’s price is currently Overvalued.
Does Imugene pay dividends?
Imugene does not currently pay dividends.
What is Imugene’s EPS estimate?
Imugene’s EPS estimate is -0.04.
How many shares outstanding does Imugene have?
Imugene has 415,835,050 shares outstanding.
What happened to Imugene’s price movement after its last earnings report?
Imugene reported an EPS of -AU$0.13 in its last earnings report, beating expectations of -AU$0.34. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Imugene?
Currently, no hedge funds are holding shares in AU:IMU
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Imugene Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.25 (-24.24% Downside)
AU$0.25 (-24.24% Downside)
Blogger Sentiment
Bullish
AU:IMU Sentiment 65%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$89.3K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-73.71%
12-Months-Change
Fundamentals
Return on Equity
-134.65%
Trailing 12-Months
Asset Growth
-39.73%
Trailing 12-Months
Company Description
Imugene
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors; and has a strategic collaboration with Eureka Therapeutics, Inc. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia.
IMU Stock 12 Month Forecast
Average Price Target
AU$0.25
▼(-24.24% Downside)
Technical Analysis
Immutep Ltd
―
Prescient Therapeutics Limited
―
Telix Pharmaceuticals
―
Noxopharm Ltd.
―
Clarity Pharmaceuticals Ltd.
―
Options Prices
Currently, No data available
---